Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of HY0001a injection in advanced malignant solid tumors
CTR20252532Phase 2Active
- Sponsor
- Huiyu Haiyue
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HY0001a in Nonhematologic neoplasms, esophageal cancer, non-small cell lung cancer (NSCLC), Cervical Cancer (CC), head and neck squamous cell carcinoma (HNSCC), sponsored by Huiyu Haiyue. Started Jul 2025; status: active.
02
Drugs
HY0001a
03
Conditions
Nonhematologic neoplasmsesophageal cancernon-small cell lung cancer (NSCLC)Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20252532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252532.